Cisplatin as second-line therapy in ovarian carcinoma treated initially with single-agent paclitaxel: a Gynecologic Oncology Group study
JT Thigpen, JA Blessing, G Olt, SS Lentz, J Bell - Gynecologic oncology, 2003 - Elsevier
OBJECTIVES: The platinum compounds are the most active agents in the treatment of
ovarian carcinoma. Phase II trials demonstrated the activity of paclitaxel in patients with …
ovarian carcinoma. Phase II trials demonstrated the activity of paclitaxel in patients with …